The new facility will serve as the company's first dedicated, fully-integrated active pharmaceutical ingredient and drug product facility for cancer, autoimmune conditions and other advanced therapies, according to Dave Ricks, chair and CEO of the company, which does business as Lilly.

The $5 billion investment represents one piece of the company's larger $50 billion expansion that began in 2020 and was renewed in Virginia in February, Ricks said. The selection process was highly competitive, with Lilly receiving more than 400 responses from 46 states.

"We did a request for information in February originally to land this site and received over 400 responses from across the country from 46 states. And we chose this site among all of those, it was a highly competitive process, and we're pr

See Full Page